MDXXF.US Pharmala Biotech Holdings Inc

Healthcare Biotechnology USA Stocks
0.0951 USD
Close of Nov 17, 2026
0.0614 0.2400
Market cap
USD 10.5M
P/E
-
P/B
7.66x
ROE
-85.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.

Is MDXXF.US undervalued?

Graham number

The Graham number of Pharmala Biotech Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharmala Biotech Holdings Inc fundamental analysis

No fundamental analysis for Pharmala Biotech Holdings Inc yet.

Pharmala Biotech Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharmala Biotech Holdings Inc

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

Full company profile